Optimer Pharma Cuts Range

Optimer Pharmaceuticals Inc., a San Diego-based developer of anti-infective products, has decreased its proposed IPO price range from $12-$14 per share to $8-$9 per share. It still plans to offer 5.25 million common shares, and trade on the Nasdaq under ticker symbol OPTR. Piper Jaffray and Jefferies & Co. are serving as co-lead underwriters. It has raised $67.7 million in VC funding from firms like ProQuest Investments, Formose Healthcare Investments and BB Biotech. www.optimerpharma.com< ?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />